What question did this study set out to answer?

This research aims to explore the expression profiles, prognostic value, and genetic alterations of lysine demethylase genes in breast cancer.

March 31, 2026Open Access

Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

ZMZohreh MirzaeiTabriz University of Medical Sciences TBTahereh BaratiTabriz University of Medical Sciences AEAmir EbrahimiBaqiyatallah University of Medical Sciences

Key Points

This research aims to explore the expression profiles, prognostic value, and genetic alterations of lysine demethylase genes in breast cancer.
Analyzed mRNA expression patterns using multiple online databases
Evaluated overall and relapse-free survival correlations with KDM genes
Conducted genetic alterations analysis focusing on amplification frequencies
Performed protein-protein interactions and pathway analyses
Investigated drug sensitivity and immune cell correlations
KDM genes showed unique expression patterns across breast cancer subtypes
Significant correlations found between KDM5B expression and overall survival
Frequent genetic alterations, particularly amplifications of KDM5B
Drug sensitivity analysis indicated that higher KDM expression correlates with lower chemotherapy response
Immune analysis linked KDMs with CD8+ T cell activity and other immune cells

Abstract

Abstract Purpose Lysine demethylases (KDMs) are critical regulators of gene expression and chromatin remodeling, playing key roles in cancer development and progression. Given their involvement in epigenetic modifications, KDM family members have emerged as potential therapeutic targets in various malignancies. This study aimed to investigate the expression profiles, prognostic value, genetic alterations, and drug sensitivity associations of KDM genes across breast cancer (BC) using comprehensive bioinformatics analyses. Methods We utilized multiple online databases, including UALCAN, bc-GenExMiner, Kaplan-Meier Plotter, cBioPortal, STRING, Enrichr, MethSurv, GSCALite, and TIMER, to analyze mRNA expression patterns, clinicopathological correlations, survival outcomes (overall survival OS and relapse-free survival RFS), genetic alterations, protein-protein interaction (PPI) networks, Gene Ontology (GO) and KEGG pathways, CpG methylation, drug sensitivity, and immune infiltration in BC and pan-cancer contexts. Results KDM genes exhibited distinct expression patterns across BC subtypes, with significant associations with OS (e.g., KDM5B, HR = 1.5, p < 0.05) and RFS. Genetic alterations, primarily amplifications, were frequent, with KDM5B showing the highest rate (18%). PPI analysis identified KDM6A, KDM6B, and KDM1A as key hubs. GO and KEGG analyses linked KDMs to histone demethylation, chromatin remodeling, and metabolic pathways. CpG methylation analysis revealed prognostic relevance, with 35 CpG sites in KDM2B significantly associated with survival ( p < 0.05). Drug sensitivity analysis showed negative correlations between KDM expression (e.g., KDM2B, r =-0.51, FDR = 1.11E-49) and chemotherapy response (e.g., Methotrexate, Doxorubicin). TIMER analysis highlighted KDMs’ immunomodulatory roles, particularly in CD8 + T cells (KDM5A, r = 0.387, p = 3.43e-36), macrophages, and dendritic cells. Conclusions Our findings provide novel insights into the multifaceted roles of KDM genes in BC, emphasizing their potential as prognostic biomarkers and therapeutic targets.

Ask AI

Helpful

Bookmark

View Full Paper